SAN FRANCISCO, Oct. 12, 2022 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) right this moment introduced that the Company will current up to date medical outcomes from the OP-1250-001 examine on the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2022), happening October 26-28, 2022, in Barcelona, Spain.
Details of the ENA 2022 poster presentation are:
| Title: | Preliminary part 1/2 outcomes from OP-1250-001, a examine of OP-1250, an oral CERAN/SERD, in topics with superior and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast most cancers (NCT04505826) |
| Session: | New medicine |
| Poster / Abstract: | 101 / PB091 |
| Date: | October 26, 2022 |
| Time: | 9:00 a.m. CEST (3:00 a.m. ET) |
A replica of the poster will probably be accessible on Olema’s web site underneath the Science part when it’s introduced on the symposium.
Company Investor Webcast and Conference Call
Olema will host a webcast and convention name for analysts and buyers to assessment knowledge introduced at ENA 2022 on Thursday, October 26, 2022, at 8:00 a.m. ET (5:00 a.m. PT). Lead examine writer, Dr. Erika Hamilton, Director of Breast Cancer and Gynecologic Cancer Research for Sarah Cannon Research Institute at Tennessee Oncology, will be a part of Olema administration for the decision. Please register for the webcast by visiting the Investors & Media part of Olema’s web site at olema.com.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical firm centered on the invention, growth and commercialization of focused therapies for girls’s cancers. Olema’s lead product candidate, OP-1250, is a proprietary, orally-available small molecule with twin exercise as each an entire estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is at the moment being evaluated each as a single agent in an ongoing Phase 1/2 medical trial, and together with CDK 4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in sufferers with recurrent, domestically superior, or metastatic ER-positive (ER+), human epidermal progress issue receptor 2-negative (HER2-) breast most cancers. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.
IR Contact:
Shane Kovacs, COO and CFO
[email protected]
Media Contact:
Ignacio Guerrero-Ros, Ph.D., Russo Partners
646-942-5604
[email protected]
